Why Aridis Pharmaceuticals Shares Are Soaring Today
Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with…
Seagen’s $43B Deal To Double Pfizer’s Early-Stage Oncology Pipeline, Seagen Says Is Right Step
Pfizer Inc (NYSE:PFE) has agreed to acquire Seagen Inc (NASDAQ:SGEN) for $229 in cash per Seagen share for a total enterprise value…
EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into an agreement with Bruder Consulting & Venture Group, a full-service strategic advisory, to assist the company in seeking FDA approval for the expanded clinical application of BRTX-100.
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.
FDA Addresses ‘Misinformation’ Concerning Delayed Approval Of Lucira Health’s COVID-19 & Flu Home Test
The FDA provided additional information about the agency’s interactions and decisions regarding the emergency use authorization (EUA) of Lucira Health Inc’s (OTC: LHDXQ)…
New York Governor, Attorney General Ask Three Pharmacy Operators’ Commitment Over Abortion Drug Access
New York government officials Governor Kathy Hochul and Attorney General Letitia James have sent a letter to CVS Health…
FDA Seeks 10% Increase In Biden’s FY 2024 Budget, Proposes Enhancing Regulatory Authorities
The FDA has requested $7.2 billion as part of the president’s fiscal year 2024 budget, $128.2 million of which the…
FDA Casts Doubts Over Roche’s Polivy Label Expansion For Untreated Lymphoma Setting
Today, the FDA Oncologic Drugs Advisory Committee is discussing the supplemental marketing application for Polivy (polatuzumab vedotin-piiq) plus Rituxan (rituximab)…
William Blair Initiates Mesoblast Soon After Its Lead Product Goes Under FDA Review In Pediatric Indication
William Blair has initiated coverage on Mesoblast Ltd (NASDAQ:MESO) with an Outperform rating and a price target of $8. Mesoblast’s lead product,…
Clene’s Amyotrophic Lateral Sclerosis Candidate Delays Disease Progression, New Data Shows
Clene Inc (NASDAQ:CLNN) announced new results from exploratory analyses, including delayed time to key clinical progression events in amyotrophic lateral sclerosis…